Category Archives: Life Extension

NO fewer than 25 community health extension workers and traditional birth attendants have been trained on hygiene promotion with a view to ending neonatal deaths in primary healthcare centres in Kwali, the Federal Capital Territory (FCT).

The training, carried out by the Golden Change for Concerned Youth Forum, a non-governmental organisation (NGO), is also aimed at equipping health workers with the knowledge to prevent infections that might occur during childbirth.

The NGOs President Williams Ngwakwe expressed worry over the continued report of new cases of infections in the area council, saying it should not to be so.

According to him, reports from UNICEF and other development partners revealed that Nigeria contributed highly to global child deaths, followed by India and Pakistan with larger populations.

We have trained community health extension workers and traditional birth attendants to build their knowledge and capacity to provide services to pregnant women to reduce neonatal infections during childbirth.

You will agree with me that nearly 70 per cent of infants deaths occur within the first month of life, largely due to infections.

When hygiene is not promoted, infections occur and when infections spread, most especially at among neonatal can lead to deaths.

- Advertisement -

We need to do everything to end maternal and child deaths. Sadly, most newborn in Kwali area council are exposed to poor hygienic conditions in their first few days of life.

Ngwakwe noted that during the early days of COVID-19, hygiene promotion played a critical role in halting continuous spread, saying hygiene promotion was key towards providing services in the health centres.

Visit link:

NGO trains health extension workers in FCT to curb neonatal deaths - International Centre For Investigative Reporting

Attractions along Coney Islands boardwalk will be getting a new lease on life under a pending city deal to extend rides and other businesses another decade save for a boutique known for quirky creations celebrating the Brooklyn amusement haven.

To help aid the iconic seaside destinations pandemic recovery following a lost 2020 season, the city Economic Development Corp is proposing a 10-year extension for the operators of Luna Park and Denos Wonder Wheel Amusement Park.

Those extensions require City Council approval an opportunity EDC and a local Council member used to make sure longtime shops and restaurants that faced steep rent hikes pre-pandemic can stay put past 2027, with a dip in their rent payments.

We wanted to see more favorable terms for the subtenants, said Councilmember Mark Treyger (D-Brooklyn), who represents the area. We need a win-win for the subtenants and Luna Park.

Treyger said the restaurants Pauls Daughter, Toms Coney Island and Rubys Bar & Grill, as well as the retailer Brooklyn Beach Shop, are poised to sign what he calls favorable subleases with Luna Park owner Central Amusement International ahead of a scheduled Dec. 16 Council vote.

I see it as relief, obviously financially, but mentally, honestly, because if I continue with my existing lease I dont know if I can afford it, said Maya Haddad Miller, co-owner of Brooklyn Beach Shop.

According to Miller, her amended lease expires in 2037 and offers more favorable terms than the one she signed in early 2020, with a rent reduction through 2029.

But one longtime boardwalk name is missing from the roster: Lola Star, a narrow gift shop selling original T-shirts and other unique Coney souvenirs.

Lola Star owner Dianna Carlin had been facing a 400% rent hike pre-pandemic and said she has not been offered a renewal or heard from anyone about the pending deals until THE CITY called.

I am disappointed and confused about why I was excluded from the other boardwalk tenants that they are assisting and helping in negotiating a fair deal, Carlin said. So we are horrified to say the least.

Luna Parks current lease dates back to 2010, after the administration of Mayor Mike Bloomberg bought the land and undertook a rezoning intended to turn Coney into a year-round destination.

The leases for Luna Park and Denos originally ran through 2020, as a temporary measure to kickstart a Coney revival. In 2013, the Council agreed to extend them through 2027.

The new lease extension would push back the expiration back again, from 2027 to 2037 though it still designates the arrangement as interim.

An extension will provide economic stability while we continue our long-term investment in Coney Island as New York City recovers from the unprecedented pandemic and its devastating effects, Alessandro Zamperla, CEO of Central Amusement, said during a Council hearing on the proposed amendment Thursday.

Dennis Vourderis, co-owner of Denos, seconded the importance of the lease extensions in his testimony. We want to continue our long-term investment in Coney Island, and this lease will help us do that, he said.

In a statement, an EDC spokesperson said the amendment will help small businesses along the boardwalk.

The resulting lease and sublease extensions will afford them greater stability, enable them to better recover from the pandemic, and help them engage in long-term investments beneficial to the Coney Island community, said the spokesperson, Mary Mueller.

In addition to the Council, the extension will also need to be approved by EDCs board and the mayor.

When the pandemic hit in 2020, the amusement district closed for an entire season for the first time ever. The shutdown coincided with what should have been celebrations for the 100th anniversary of Denos Wonder Wheel, a major draw.

Business along the historic boardwalk suffered. A co-owner of Rubys Bar & Grill, Michael Sarrel, said his restaurant earned 70% less in 2020 than the year before.

We were able to still do some business because we had outdoor space, Sarrel told THE CITY, noting that his eatery fared relatively better than ones that did not.

At Thursdays Council hearing, an EDC official said the proposed lease extension would help businesses recoup losses incurred because of the government closures and will support their continued efforts and investment in the amusement area.

By approving the proposal, the Council will ensure that the unique and iconic Coney Island Amusement area and community continues to thrive for future generations, said the official, Sean Freas, EDCs vice president of portfolio management.

During the pandemic, Central Amusement approached EDC for a lease extension through 2040 to help get support from lending institutions as well as maintain long-term security, the Brooklyn Paper reported last October.

At the time, an EDC spokesperson said: Any lease extension without a competitive process raises issues of fairness.

THE CITY reported this spring that Luna Park has delayed a planned expansion, including a new adventure park and water flume ride, originally set for 2019 and 2020 but now promised for next year.

Treyger said he insisted that Central Amusement subtenants also benefit from an extension because they were an afterthought in the 2009 Bloomberg plan.

Treyger said theres still time for Zamperla and Lola Star to agree on a lease.

But folks have to negotiate really in good faith on both sides, he said.

Sign up and get the latest stories from THE CITY delivered to you each morning

Read this article:

Threatened Coney Island Boardwalk Businesses Get a New Lease on Life Except One - THE CITY

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006139/en/

(Photo: Business Wire)

The Food and Drug Administration (FDA) granted the EUA for EVUSHELD for pre-exposure prophylaxis of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination, as well as those individuals for whom COVID-19 vaccination is not recommended. Recipients should not be currently infected with or had recent known exposure to a person infected with SARS-CoV-2.

Myron J. Levin, MD, Professor of Pediatrics and Medicine, University of Colorado School of Medicine, US, and principal investigator on the PROVENT trial, said: Millions of people in the US and around the world remain at serious risk for COVID-19 because their immune systems do not generate a sufficient immune response, even after receiving all recommended doses of vaccine. I am excited to offer my patients EVUSHELD as an easily-administered new option that provides long-lasting protection that could help them return to their everyday lives.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: We are proud to play a leading role in fighting the COVID-19 pandemic and, with EVUSHELD, we now have the first antibody therapy authorized in the US to prevent COVID-19 symptoms before virus exposure, while also providing long lasting protection with a single dose. EVUSHELD neutralizes all previous SARS-CoV-2 variants to date, and we are working quickly to establish its efficacy against the new Omicron variant. We thank our clinical trial participants, the investigators, scientists, and government agencies and our colleagues at AstraZeneca who have all contributed to the development of EVUSHELD.

Brian Koffman, MDCM (retired), MS Ed, Co-Founder, Executive Vice President and Chief Medical Officer of the CLL (Chronic Lymphocytic Leukemia) Society, US, said: One of the primary questions I keep getting asked by patients is When can I hug my grandchildren again? As a physician and person with a weakened immune system, l am filled with hope now that EVUSHELD will soon be available to those who cant count on vaccination alone to provide the protection they need.

EVUSHELD is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorized in the US for COVID-19 pre-exposure prophylaxis and the only COVID-19 antibody delivered as an intramuscular dose (150mg tixagevimab and 150mg cilgavimab).

About 2% of the global population is considered at increased risk of an inadequate response to a COVID-19 vaccine.1,2 About seven million people in the US are immunocompromised and may benefit from EVUSHELD for pre-exposure prophylaxis of COVID-19.1,3,4 This includes people with blood cancers or other cancers being treated with chemotherapy, and those taking medications after an organ transplant or who are taking immunosuppressive drugs for conditions including multiple sclerosis and rheumatoid arthritis.5-9

The primary data supporting the EVUSHELD EUA are from the ongoing PROVENT Phase III pre-exposure prevention trial, which showed a statistically significant reduction (77% at primary analysis, 83% at median six-month analysis) in the risk of developing symptomatic COVID-19 compared to placebo, with protection from the virus continuing for at least six months. More follow-up is needed to establish the full duration of protection provided by EVUSHELD. Data from the Phase III STORM CHASER post-exposure trial and the EVUSHELD Phase I trial also supported the EUA. EVUSHELD was well-tolerated in the trials.

EVUSHELD and SARS-CoV-2 variants

Studies are underway to provide information on the impact of the new Omicron variant (B.1.1.529) on EVUSHELD.10,11 Of the Omicron binding site substitutions relevant to EVUSHELD that have been tested to date in preclinical assays, none have been associated with escape from EVUSHELD neutralization.10,11 In vitro findings demonstrate EVUSHELD neutralizes other recent emergent SARS-CoV-2 viral variants, including the Delta and Mu variants.10

EVUSHELD is being developed with support from the US government, including federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, under Contract No. W911QY-21-9-0001.

AstraZeneca has agreed to supply the US government with 700,000 doses of EVUSHELD. The US government has indicated that it plans to distribute these doses to states and territories at no cost and on a pro rata basis.

AstraZeneca is progressing with filings around the globe for potential emergency use authorization or conditional approval of EVUSHELD in both COVID-19 prophylaxis and treatment.

EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under Section 564(b)(1) of the Food, Drug and Cosmetic Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

IMPORTANT SAFETY INFORMATION

EVUSHELD (tixagevimab co-packaged with cilgavimab) has not been approved, but has been granted an Emergency Use Authorization (EUA) by FDA. There are limited clinical data available and serious and unexpected adverse events may occur that have not been previously reported with EVUSHELD use.

Contraindication:

EVUSHELD is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to any component of EVUSHELD.

Warnings and Precautions:

Hypersensitivity Including Anaphylaxis

Serious hypersensitivity reactions, including anaphylaxis, have been observed with IgG1 monoclonal antibodies like EVUSHELD. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive therapy. Clinically monitor individuals after injections and observe for at least 1 hour.

Clinically Significant Bleeding Disorders

As with any other intramuscular injection, EVUSHELD should be given with caution to individuals with thrombocytopenia or any coagulation disorder.

Cardiovascular Events

A higher proportion of subjects who received EVUSHELD versus placebo reported myocardial infarction and cardiac failure serious adverse events. All of the subjects with events had cardiac risk factors and/or a prior history of cardiovascular disease at baseline. A causal relationship between EVUSHELD and these events has not been established. Consider the risks and benefits prior to initiating EVUSHELD in individuals at high risk for cardiovascular events, and advise individuals to seek immediate medical attention if they experience any signs or symptoms suggestive of a cardiovascular event.

Adverse Reactions:

The most common adverse events are headache, fatigue and cough.

Use in Specific Populations:

Pregnancy

There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. EVUSHELD should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

Lactation

There are no available data on the presence of tixagevimab or cilgavimab in human milk or animal milk, the effects on the breastfed infant, or the effects of the drug on milk production. Maternal IgG is known to be present in human milk.

Pediatric Use

EVUSHELD is not authorized for use in pediatric individuals under 12 years of age or weighing less than 40 kg. The safety and effectiveness of EVUSHELD have not been established in pediatric individuals.

AUTHORIZED USE

EVUSHELD (tixagevimab co-packaged with cilgavimab) is authorized for use under an EUA for the pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

EVUSHELD has been authorized by FDA for the emergency use described above. EVUSHELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.

EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

LIMITATIONS OF AUTHORIZED USE

See Full Fact Sheet for Healthcare Providers for examples of medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination, the justification for emergency use of drugs during the COVID-19 pandemic, information on available alternatives, and additional information on COVID-19.

The FDA Letter of Authorization is available for reference, as well as the Fact Sheet for Patients, Parents And Caregivers.

SARS-CoV-2 Viral Variant

There is a potential risk of treatment failure due to the development of viral variants that are resistant to tixagevimab and cilgavimab administered together. Prescribing healthcare providers should consider the prevalence of SARS-CoV-2 variants in their area, where data are available, when considering prophylactic treatment options.

Reporting Adverse Events

The prescribing healthcare provider and/or your designee must report all SERIOUS ADVERSE EVENTS and MEDICATION ERRORS potentially related to EVUSHELD within 7 calendar days from the healthcare providers awareness of the event (1) by submitting FDA Form 3500 online, (2) by downloading FDA Form 3500 and then submitting by mail or fax, or (3) contacting the FDA at 1-800-FDA-1088 to request this form.

In addition, please fax a copy of all FDA MedWatch forms to AstraZeneca at 1-866-742-7984.

Report adverse events by visiting https://contactazmedical.astrazeneca.com, or calling AstraZeneca at 1-800-236-9933.

Notes

EVUSHELD

EVUSHELD, formerly known as AZD7442 is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein13 and were optimized by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. The half-life extension more than triples the durability of its action compared to conventional antibodies and could afford up to 12 months of protection from COVID-19 following a single administration;14-16 data from the Phase III PROVENT trial show protection lasting at least six months.17 The reduced Fc receptor binding aims to minimize the risk of antibody-dependent enhancement of disease - a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.18 EVUSHELD is delivered as an IM dose of 150mg tixagevimab and 150mg cilgavimab administered in two separate, consecutive injections.

In August 2021, AstraZeneca announced that EVUSHELD demonstrated a statistically significant reduction in the risk of developing symptomatic COVID-19 in the PROVENT trial; efficacy was 83% compared to placebo in a six-month analysis announced on November 18, 2021. In October 2021, AstraZeneca announced positive high-level results from the EVUSHELD TACKLE Phase III outpatient treatment trial. EVUSHELD is also being studied as a potential treatment for hospitalized COVID-19 patients as part of the National Institute of Healths ACTIV-3 trial and in an additional collaborator hospitalization treatment trial.

Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit http://www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

References

View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006139/en/

Continued here:

EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of...

A Regina mother is shocked she was given a COVID-19 rapid test kit that had an expiration date from the summer.

When Sarah Wilkie's two-year-old came down with a cough last week, shetook her to COVID-19 drive-thru testingsitein Regina. While in line Wilkie was given rapid test kits.

"I didn't look at it, I just was happy to get rapid tests and went on my way," said Wilkie.

On Sunday evening Wilkie went again to the drive-in test clinic to get herself tested and was given more rapid tests.

"The person who was giving me the swab mentioned they do say they're expired, but the manufacturer said that it was still good for at least six months afterwards."

This morning Wilkie saw on social mediaa number of other people around the province had also been given test kits past their expiry date.

Wilkie did some research and foundthe Health Canada'sCOVID-19 website said the test kits were still viable up to10 months past the expiry date on the box.

For example, if the expiry date printed on the label was June 9, 2021, the new expiry date would be April 9, 2022.

Any boxes that have an expiration date in 2022 can be used four months past the expiry date.

Late Monday morning the Saskatchewan Health Authority sent out a tweet stating they've received questions about the kit, and that the expiry dates were extended by Health Canada.

And Monday afternoon the Saskatchewan Public Safety Agencyissued a statement saying on Oct. 18 Health Canada authorized "an Expansion of Use to the BD VeritorSystem for Rapid Detection of SARS-CoV-2 authorization for a shelf life extension from 12 to 16 months."

The SPSA said the instructions for use and packaging were not updated to reflect this change. In Saskatchewan, information is sent out to each distribution site with these kits to explain the apparent discrepancy and to alleviate any confusion.

"Unfortunately, we cannot speak at to why a client was not informed about the extension of the expiry date for these tests," the SPSA said.

The SPSA said the shelf life extension applies to kits already handed out, as well as those being given out currently. It said any questions related to this should be directed to Health Canada as they originally adjusted the shelf life extension.

Wilkie said she isn't concerned the tests are invalid, "but I'm still upset about why are we getting these tests now?

"The ones I got when my daughter was tested expired this Aug. 2, and the ones they gave me yesterday were July 23," she said.

"These were in existence and just not given out to the public, or tothe schools or anybody, obviously, if they're only giving them out now."

One person responding to her tweet did say there was a letter in their test kit that explained it had not expired.

Wilkie said the province needs to communicate better with the public around this issue.

"If you're frazzled parent with a sick kid, are you going to just not notice and then see that expiry date and think that all your tests were inaccurate?

"I definitely want to know where these were, why we weren't given them months ago when they maybe could have been helpful in preventing the catastrophe of the fourth wave or at least mitigating it somewhat," Wilkie said.

Read this article:

Expired rapid test kits are still valid, says SHA - CBC.ca

New York, United States The Global Black Cumin Seed Oil Market Report 2021-2028 (Forecast Period) offers an in-depth study of market growth factors, future evaluation, country-level analysis, market distribution, and competitive landscape study of significant industry players. Almost every segment of the global Black Cumin Seed Oil market has been thoroughly examined in this research report. The segment analysis offers critical opportunities available in the global market through leading segments. The geographical analysis of the global Black Cumin Seed Oil market assists readers in gaining a comprehensive grasp of the evolution of the various geographic markets in recent years as well as in the future. In addition, the report provides a comprehensive overview of the vital dynamics of the global Black Cumin Seed Oil market, including market influence and market effect factors, drivers, threats, constraints, trends, and prospects. Additionally, various types of analysis, such as qualitative and quantitative, are included in the research study.

This report contains information about the manufacturer, such as shipment, pricing, revenue, gross profit, interview record, business distribution, and other information that helps the consumer learn more about the rivals products and services. This report also covers data on all global regions and nations, including market size, volume, and value, as well as price data. Due to the coronavirus condition, the report estimates that the global Black Cumin Seed Oil market would reach XX Million USD in 2020, with a CAGR of XX% from 2021-2028.

NOTE: Our team is researching Covid-19s impact on numerous business verticals and countries to better understand markets and sectors. This studys update will cover the latest scenario, economic slowdown, and COVID-19 influence on the industry.

Request Free Sample Report Black Cumin Seed Oil Industry Outlook, Click Here @

Industrial Analysis of Black Cumin Seed Oil Market: Life Extension, Earthoil Plantations, Nuverus, FLAVEX Naturextrakte GmbH, Henry Lamotte OILS GmbH, BioPraep, Kerfoot Group, Henry Lamotte Oils GmbH, Omega Pharma, among others.

In addition, the research includes in-depth information on attributes such as new developments in the Black Cumin Seed Oil market, total revenue, sales, annual production, government regulations, and trade restrictions in some countries. Black Cumin Seed Oil This report covers current product improvements and provides an outline of possible regional market shares.

Market Dynamics:-

In addition to comprehending the fundamental characteristics of the Black Cumin Seed Oil industry, the study covers many volume trends, the pricing history, and the market value of the Black Cumin Seed Oil market. A number of prospective growth drivers, constraints, and opportunities are also examined in order to provide a more comprehensive understanding of the market.

An in-depth analysis of the Black Cumin Seed Oil market is provided in this research, as well as market shares and growth opportunities by product type and application, as well as by major manufacturers, important regions, and countries.

It is the focus of this study to examine the impact of the Covid-19 outbreak on the Black Cumin Seed Oil, which includes a supply chain analysis, an assessment of the impact on the market size growth rate under various scenarios, and an examination of the measures that companies should take in response to the COVID-19 epidemic.

=>> Segmentation by Type:

Food Grade, Cosmetic Grade

=>> Segmentation by Application:

Soap, Health Food, Care Products (Massage Oils, Skin Care Products)

Impact of COVID-19:

The study examines the impact of the Coronavirus (COVID-19) on the industry. Since the outbreak of the COVID-19 virus in December of this year, the sickness has spread to almost 180 nations around the world, prompting the World Health Organization to declare it a public health crisis. The global ramifications of the COVID-19 are already being felt, and they will have a considerable impact on the Black Cumin Seed Oil industry by 2021.

Flight reschedules Many countries have declared emergencies due to the COVID-19 epidemic, causing restaurants to close and indoor activities to be banned. The stock market has been volatile and corporate confidence has fallen due to the outbreak.

COVID-19 has the potential to have three major effects on the global economy: by directly impacting production and demand, by causing supply chain and market disruption, and by having a financial impact on enterprises and financial markets.

The following are the reasons for purchasing the Black Cumin Seed Oil market report:

The research provides in-depth coverage of the industry and the most important market trends, as well as the influence of the coronavirus. In addition to historical and forecasted market data, the research provides demand, application information, price trends, and the company shares of the major players by geography, among other things. The market size, both in terms of volume and value, is segmented according to application, type, and geography in the report.

Throughout this report, we examine the global market from the perspectives of five major geographies: Asia-Pacific [China, Southeast Asian countries such as India and Japan, Korea, Western Asia], Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America [United States, Canada, Mexico], South America [Brazil, Argentina, Columbia, Chile, Peru], and the Middle East & Africa [GCC, North Africa, South Africa, Egypt]

At the same time, we categorize according to the type and application of the product. More importantly, the study offers market data for major countries depending on the kind of product and the application. Finally, the study gives a full biography of the leading company, as well as an analysis of its data information.

Table of Content:

Major highlights of the Black Cumin Seed Oil market report:

Black Cumin Seed Oil Market 2021, Black Cumin Seed Oil Market Analysis, Black Cumin Seed Oil Market Forecast, Black Cumin Seed Oil Market Trends, Black Cumin Seed Oil Market Research, Black Cumin Seed Oil Market Trend, Black Cumin Seed Oil Market Sales & Price, Market CAGR Competitive Landscape, Black Cumin Seed Oil Market Growth

Contact Us:

Market Research Store244 Fifth Avenue, Suite N202New York, 10001, United StatesTel: +1 (844) 845-5245USA/Canada Toll-Free No.+1 (855) 465-4651Email: [emailprotected]|Website: http://www.marketresearchstore.com

Excerpt from:

Global Black Cumin Seed Oil Market Future Growth Outlook 2021-2028 Emerging Trend, Growth Opportunities, Industry Size, Share, Key Players | Life...

UNIVERSITY PARK, Pa. As the holidays approach, many people mull over gift selection. Giving someone food is a thoughtful and kind gesture. Giving someone food poisoning? Not so much.

To help gift-givers spread holiday cheer rather than foodborne illness, Martin Bucknavage, senior food safety extension associate in Penn State's College of Agricultural Sciences, shared advice for giving and receiving food safely this holiday season:

Stick with shelf-stable items. Items such as cookies and bread can be shipped easily. But items that require refrigeration are trickier to ship and could spoil if shipped incorrectly.

Follow approved recipes. Not all recipes from the internet are safe. If you decide to make canned food, follow a research-based recipe. Visit the Penn State Extension website for recipes and guidance on safe canning, from salsa to blueberries. In addition, some foods, such as soups, require pressure canning. For many, it may be easier to package the soup ingredients together in a jar for the recipient to make the soup themselves.

Avoid certain homemade canned goods. If a research-based recipe or procedure does not exist, then the food should not be made. For example, Bucknavage explained, sometimes people want to make homemade flavored oil by adding garlic or onions to jars with oil. While commercial manufacturers can do this because they have specific procedures, these procedures require higher levels of control than can be accomplished by the home canner.

If you give something that requires refrigeration, make sure the recipient knows that. They might take it home and put it on the counter. If the item needs to be refrigerated or frozen, write keep refrigerated or keep frozen on the package.

When receiving food as a gift, ask questions. Should I refrigerate this? How did you make this? How long will this keep?

Consider allergen concerns. Many people have allergies some life-threatening. If the item contains peanuts or walnuts, the container should clearly state that. Also, be aware that items in your kitchen could contaminate food. For example, if you snack on peanuts while baking cookies, those peanut allergens could spread to the cookies.

Give the gift of food safety. A high-quality food thermometer could prevent undercooking. An oven-safe thermometer for cooking a turkey or a roast is especially useful. A set of cutting boards also could make a wonderful gift for the home chef. Bucknavage said he likes to use the hard plastic ones for meat because they are easy to clean and dishwasher safe.

Hungry for more tips? The Penn State Extension website contains an abundance of resources on food safety.

See original here:

Giving gifts of food this holiday season? Chew on these food safety tips - Penn State News

Private space stations may end up being a key stepping stone on humanity's path to Mars.

NASA aims to put astronauts on the moon in this decade and on the Red Planet in the 2030s. To help make these ambitious goals a reality, the agency is performing lots of research aboard the International Space Station (ISS) monitoring astronaut health, behavior and performance on year-long orbital missions, for example, to better understand the effects of long-duration spaceflight on the human body and mind.

But the venerable ISS, which is 23 years old and has hosted rotating astronaut crews continuously since November 2000, may not be around long enough to see this work through, according to a new report by the NASA Office of Inspector General (OIG).

Related: Building the International Space Station (photos)

"Under the Agency's [NASA's] current plans, both health risk mitigation and technology demonstrations will not be complete by 2030 the expected retirement date of the ISS," states the 41-page report, which was released on Tuesday (Nov. 30). (The ISS is officially approved to operate only through 2024, but "an extension to 2030 is likely," the report notes.)

This outcome would not take NASA by surprise. The agency is encouraging the development of private space stations to fill any orbital research gaps that may arise, with the goal of having at least one such commercial outpost up and running by 2028. And its work toward this end has been productive, according to the report.

"We found that the Agency's near-term actions show promise, with NASA's recent efforts resulting in market interest and growth, especially for private astronaut missions," the report states.

For example, the Houston company Axiom Space plans to fly four private crewed missions to the ISS aboard SpaceX Crew Dragon capsules in the next two years. The first of those flights is right around the corner, with launch targeted for February 2022. The company has tapped veteran NASA astronauts to command the first two of those flights and may do so for the others as well.

Axiom also aims to launch a commercial module to the ISS in September 2024, then send three more modules up over the next three years.

"With the delivery of the fourth module, Axiom Station will have the capability to be independent of the ISS and can then separate to become an independent, next-generation space station with upgraded crew quarters, increased payload capacity and a dedicated manufacturing and research lab module," Axiom Chief Technology Officer Matt Ondler told Space.com via email recently.

"This timeline supports the current planned end of ISS life, so there should be a seamless transition with no gaps in human continuous presence in LEO [low Earth orbit]," Ondler added.

The OIG report is less sanguine about timelines, stating that NASA "faces significant challenges with executing its commercialization plan by 2028 or even 2030 meaning that without further extension of the ISS, a gap in availability of a low Earth orbit destination is likely."

Those challenges "include limited market demand, inadequate funding, unreliable cost estimates and still-evolving requirements," the report adds. It also notes that risks will rise for crewed missions to deep-space destinations such as the moon and Mars if NASA cannot finish its prep work in LEO.

"Furthermore, without a destination, the nascent low Earth orbit commercial space economy would likely collapse, with cascading impacts to commercial space transportation capabilities, in-space manufacturing, and microgravity research," the report states.

The new report touches on a number of other issues as well. For example, its researchers investigated the space station's structural integrity, an issue that received increased attention recently after the discovery of several cracks in Russia's Zvezda module, which launched to orbit in July 2000.

The report recommends that Kathy Lueders, the head of NASA's Space Operations Mission Directorate, make sure that the risks associated with the Zvezda cracks "are identified and mitigated prior to agreeing to an ISS life extension."

In a written response included in the report, Lueders states that NASA "partially concurs" with the recommendation. The agency agrees that finishing risk-assessment work on the cracks is essential, as are the Russian federal space agency's efforts to find and fix them. But NASA does not agree that such work must be completed before an ISS life extension can be granted, Lueders writes.

Research for the new report, which is called "NASA's Management of the International Space Station and Efforts to Commercialize Low Earth Orbit," was performed from November 2020 to October 2021, OIG officials said. You can read the full report for free here.

Mike Wall is the author of "Out There" (Grand Central Publishing, 2018; illustrated by Karl Tate), a book about the search for alien life. Follow him on Twitter @michaeldwall. Follow us on Twitter @Spacedotcom or on Facebook.

Original post:

Private habitats, not just the International Space Station, may be needed to get astronauts to Mars: report - Space.com

Lawrence Livermore National Laboratorys (LLNL) seventh annual early and mid-career awards program included five scientists whose work has made a significant impact on NIF & Photon Science research.

LLNL Director Kim Budil announced that 12 LLNL scientists and engineers were selected as award recipients for the 2021 Early and Mid-Career Recognition (EMCR) Program, which recognizes scientific and technical accomplishments, leadership, and future promise demonstrated by Lab scientists and engineers early in their careers four to 16 years since they received their most recent degree.

Our early and mid-career staff are our future leaders, Budil said. Through these awards, we recognize their exceptional accomplishments and provide an opportunity to further enhance their careers at the Lab.

Winners receive a cash award and institutional funding (approximately equivalent to 20 percent support for one year) to pursue research activities in their area of interest.

Among the award recipients was former Deming High School graduate Jeremy Lenhardt, son of Cheryl and Randy Lenhardt of Deming.

Jeremy Lenhardt

Since joining LLNL in 2011 as a postdoctoral researcher, Jeremy Lenhardt has made significant contributions to multiple programmatic areas critical to national security, including NIF target materials (JX foams), the creation of additive manufacturing (AM) resins (DIW Inks), the formulation of a new chemically blown foam for a critical weapon component, the development of alternative methods for adding porosity to AM elastomers, and the identification of critical deficiencies and fixes for the production of cellular silicone gumstocks.

The JX foams Lenhardt created in his early time at LLNL are used in the fabrication of NIF targets today. The Llama series of DIW resins have been extensively used by LLNL and the Kansas City National Security Complex for development of weapon components, including approximately 25 combined in the W80-4 Stockpile Life Extension Program (LEP) and W87-1 Warhead Modification Program. New blown foams are used in a critical LEP component.

I am incredibly grateful to be at such an incredible laboratory winning this award would not be possible without the support and work of fellow scientists across the lab, said Lenhardt, who is now the deputy group leader in the High Performance Materials group in the Physical and Life Sciences Directorates Material Science Division.

With the award funding, he plans to look for opportunities to marry polymer additive manufacturing with the field of polymer mechanochemistry. He said by using non-traditional AM scaffolds, we can now have the advantage of directing chemistry through the application of mechanical force. This has implications in self-healing, self-reporting, and elastomers.

The 2021 EMCR winners include:

Jason Chou

Jason Chou has had a remarkable career as a subject matter expert and pioneer in radio frequency photonics. This is a novel field that combines high-speed electronics and ultra-fast optics to target high-performance applications that cannot be met by either discipline alone.

He has been directly responsible for growing and developing this new field within the NIF&PS Department of Defense Technologies (DODT) program, targeting high-speed, high-dynamic range applications including diagnostic instrumentation, radar, and secure communications. He has attracted both internal and external hires to come and join the enterprise, acting as a thoughtful leader and a career mentor.

Chou has been at the Lab for 11 years and now serves as the group leader for radio-frequency (RF) photonics.

Upon hearing of the award, Chou said: Its really a result of all the talented people Ive worked with over the years at the Lab. Real progress doesnt happen with just one person, its always a team effort. This award is a testament to the dedication, inspiration, and perspiration of so many. I am truly blessed for the vast number of opportunities and amazing people I get to be surrounded by each day at LLNL.

With his award money, he plans to further study the how light can be used to improve the way we communicate and meet national security needs across the electromagnetic spectrum. One extremely interesting area for Chou is the potential of integrated RF photonics, aimed at lowering size, weight, power, and cost. He also would like to build strategic partnerships with universities, industry, and other government labs to further advance the innovative technologies the Lab is developing in the RF photonics group.

Amy (Lazicki) Jenei

Amy (Lazicki) Jenei, a Physical and Life Sciences physicist and the project leader for the plasma equation-of-state (EOS) program in Weapons Physics and Design (WPD) for more than five years. Jenei was the lead author of a study, published earlier this year inNature,that used NIF to successfully measure carbon at pressures reaching 2,000 GPa5 times the pressure in Earths core (see Experiments at NIF Probe Carbon at Record Pressures).

She is innovative in her approach to acquire high-pressure plasma EOS data in support of WCI programs and stockpile stewardship efforts. Jenei started her Lab career in 2004 as a grad student, went on to become a postdoctoral researcher in 2010, and now is a staff physicist studying material properties at extreme conditions.

I was surprised and very honored to get this recognition, she said.

Chris Weber

Chris Weber has maintained a steady pace of significant technical accomplishments and innovative program contributions. In his nine years at the Lab, Weber has already played a leading role in more than a half-dozen different projects within LLNLs ICF program.

His surprising discovery of the importance of viscosity in NIF hot spots changed the inertial confinement fusion (ICF) communities view of the character of ICF implosions. His high-resolution, 3D simulations showed that NIF hot spots are in fact highly viscous and essentially precluded the formation of turbulence under NIF implosion conditions. This discovery represents an important scientific contribution to the understanding of ICF and to the ICF community.

Webers Lab career actually started with an internship in the Weapons and Complex Integration HEDP (high energy density physics) summer program during grad school.

Im honored to be recognized, he said. It makes me think of the countless mentors and peers that have helped my work and inspired me. I still remember going to my first few technical meetings here as a new hire and being energized by the level of discussion and the collaborative atmosphere.

With additional funds, Weber would like to build on the1.3 megajoule NIF experimentwith applications to energy or stockpile stewardship.

Alex Zylstra

Alex Zylstra came to LLNL as an ICF/HED experimentalist from Los Alamos National Laboratory (LANL) three years ago, where he served as a distinguished postdoc. A participant in theNIF-MIT Ph.D. Thesis Program, he was hired by LLNL in September 2018. During his time as a LANL postdoc, Zylstra was experimental lead for the beryllium implosion campaign on NIF.

He is the top class of ICF Program experimentalists, showing a deep level of understanding about ICF implosions. Through his work, he positioned himself to be experimental lead of the ICF programs Hybrid-E implosion effort, an effort which attempts to take the best elements of past designs and utilize the Labs data-based understanding of the key physics factors that control symmetry and performance to position the ICF Program to field large-scale (>1,000 micron inner radius capsules) ignition-relevant implosions that utilize NIFs full power and energy capacity. The recent results from the Hybrid-E campaign will be the biggest results in the fusion community this year and perhaps this decade.

Im very grateful and happy to receive an early career award from the Lab, Zystra said. It is gratifying to have my work recognized; these projects are a team effort, so I also am very thankful for my many colleagues and team members that have made all of my work possible.

As an ICF expert, Zystra plans to expand on his work with the award funding. This is an extremely exciting time for the ICF community with our recent results from NIF, he said. Im quite interested in exploring how we can use these high-yield implosions to study science beyond the fusion program, such as novel nuclear physics and astrophysics, and the institutional funding is a great opportunity to support this kind of work.

The program also honored:

Peter Caldwell, who as staff scientist and deputy group leader for the Cloud Processes Research and Modeling group is a world-renowned expert in climate modeling.

Brian Daub, who has achieved technical excellence and leadership in Design Physics and Nuclear Threat Reduction.

Paul Durack, a physical oceanographer whose research expertise has filled an essential gap in the LLNL Climate Program since he joined the Lab in 2011.

Kim Knight, who has emerged as a nationally and internationally recognized leader in the field of nuclear forensics, driving the renaissance in analysis of historical nuclear debris and supporting many agencies in these endeavors.

Carol Meyers, associate program leader for Nuclear Weapons Enterprise Evaluation and Planning within the Weapons Infrastructure Program in WCI.

Geoff Sanders, an 11-year LLNL computational scientist whose research involves a high level of technical intricacy on multiple concurrent projects.

Megan Syal, who was appointed project lead for Planetary Defense within WCI in 2018 and has served as a group leader in the Design Physics Division since 2019.

Read the original:

Lawrence Livermore National Laboratory awards Jeremy Lenhardt - Deming Headlight

AstroscaleHoldings Inc. (Astroscale), provider ofsatellite servicing andlong-term orbital sustainabilityacross all orbits, announcedit closed its Series F round with additional funding of U.S.$109million from a group ofnewinvestors.Led byinvestors from THE FUND Limited Partnership in Japan,with participation frominternational investorsincludingSeraphim Space Investment Trustplc (SeraphimSpace)in the United KingdomandDNCA Invest Beyond Global Leaders,a sub-fund of the umbrella structured fundDNCA Investincorporated under the laws of the Grand Duchy of Luxembourg,managed by DNCA Finance,a Limited Partnershipin France. Thisis thelargestfunding roundin the companys historyandbrings the totalamountraised to U.S.$300 million,affirming investors confidence in therapidly expandingon-orbit servicingmarket.

SinceAstroscalesinception in2013,we have dedicated ourselves tosolvingthe technological, economic and policy aspectsofsatellite servicingto buildasustainableinfrastructurefor a thriving space ecosystem, said Nobu Okada, Founder & CEO ofAstroscale. This latest round of funding willdramaticallyaccelerateour abilityto makeon-orbit servicingroutine by 2030.It alsoshowsthatinvestorsaround the world,acknowledge the tremendouspotential in theemergingon-orbit servicing market, whichwill revolutionize thefuture of space.

The Series F funding round represents another significant milestone forAstroscale,and willrapidlyadvance therange ofmissions and servicesthat thecompanyis developingglobally.The End-of-Life Services byAstroscale-demonstration (ELSA-d)missionsuccessfully completed its first technical demonstrationinorbitin August,andAstroscaleispreparing for the capture without tumblingphase,which is expected to becompletedby the end of the calendar year.In Japan, the Active Debris Removal byAstroscale-Japan (ADRAS-J) spacecraft, which was selected by the Japan Aerospace Exploration Agency for Phase I of its Commercial Removal of Debris Demonstration Project, will enter the assembly phase in early 2022. In the UnitedKingdom, the team was recentlyawarded a bid to study the removal of two defunct satellitesfrom the UK Space Agency and is maturing the End-of-Life technology and capability towards a commercial service offering by 2024. TheAstroscaleU.S. and Israel teams are meeting milestones fortheLife Extension In-Orbit(LEXI) spacecraftandhave successfullyexecuted key tests.

The market opportunity for on-orbit servicing continues to develop andmultiple sources projectsignificant growth by the end of the decade.This includes not only end-of-life,activedebris removal,in situspace situational awarenessand life extensionservices, but many other capabilities thatwill actively contribute to the sustainable use of spaceandmaximize the use of expensivesatelliteassets in a sustainable manner.This expansion of serviceswill include in-orbit manufacturing,as well assatelliteassembly,refuelling, recycling and morein the near future.

Multiple new investors highlight the importance of taking steps to develop servicing technologies andaddress issues of sustainability.The investment fromSeraphimSpace,the worlds first listed fund focused on space technologies and a globally recognized leader in identifying promising space companies, isa strong signal thatAstroscaleis leading the development of the servicing market.The investment fromTHE FUND, one of the leading independent cross-over growthcapitalorganizationsin Japan, represents a long-term commitment from local financial marketsfor sustainable space utilization.Additionally, investmentfrom AXA Life Insurance Co.,Ltd. underpinsthefuturepotentialofthespacesector,including satellite services.

The long-term sustainable health of the space sector is becoming ever more important with tens of thousands of satellite launches planned in the coming years, saidMarkBoggett, CEO of SeraphimSpace.Astroscaleis already the category leader, the trailblazer in the globalon-orbit servicing market. Its founder and CEO Nobu Okada is credited worldwide as a key figure in galvanizing the space industry into action. The ball is now firmly rolling on regulation and self-regulation to protect the space environment. We believe that now is the optimum time to invest into this emerging market that will be worth billions over the coming decades.

This funding round will allowAstroscaletopioneersafe and cost-effective space capabilities across the servicing ecosystem, expand regional facilities for mass production in Japan, the United Kingdom, and the United States, and support global growth.Since its last funding round in October 2020,Astroscalehasincreased its global team by more than60 percent and now boasts approximately 250teammembers around the globe.

Investors inAstroscaleSeries F Round:

Go here to see the original:

Astroscale's Largest Funding Round to Date Closes, Bringing Total Capital Raised To US $300 Million SatNews - SatNews Publishers

BALTIMORE -- Ravens tight end Mark Andrews had finished his pregame warm-ups and was walking off the field in Chicago on Nov. 21 when he saw a sign that immediately caught his attention.

In purple lettering, it read: T1D.

Few in Soldier Field knew what it meant, but Andrews did -- its shorthand for Type 1 diabetes.

Andrews veered over to 10-year-old Rhys Kinney, who made the placard for the Pro Bowl tight end. After giving Kinney a fist bump, Andrews told him: Anything you want to do is possible."

A Type 1 diabetic since childhood, Andrews has made it his mission to motivate those diagnosed with this chronic condition at a young age. His message: Dont let this disease define you.

How good is your coach on 4th-down calls? Mark Andrews inspires other diabetics Stefon Diggs embracing leadership role Browns' offense has cratered Elijah Mitchell: From 6th-rounder to AD comp Broncos wrestle history for division lead

Andrews goal has never been to become the best tight end with diabetes. He wants to become the best tight end in football, and his 22 receiving touchdowns since 2019 -- the most by any tight end -- are a testament to his determination. Still, Andrews knows his success can make a difference off the field.

Type 1 diabetes is a 24/7 fight, and for a young kid to see someone performing at the highest level, I think thats encouraging, Andrews said. Thats a big moment.

Kinney, who lives approximately 30 miles outside of Chicago, was diagnosed with diabetes at the age of 5. He was in the hospital and scared, according to his father, Brett. His one question was whether he would ever play baseball again.

"Its not something that I can relate to him about, Brett said. "I can say that I can understand him getting frustrated, but I cant say that I can understand from experience.

I just like to get him around people like Mark so that he can laugh and make a joke about it, and theyre like, 'Yeah, I know exactly what youre talking about. That sucks. Why I really appreciate Mark is he made Rhys feel special, and not different. He has plenty of days where he feels different.

Rhys and Brett reached out to the Ravens a few weeks before they traveled to the road game against the Bears, and they soon received a letter. Andrews wrote to Rhys and explained diabetes made him the person he is today, and that he should view the disease as a benefit, not a hindrance. Andrews said he was forced to grow up very quickly because of his condition. At an early age, he learned how to count the carbs he would consume and calculate the correct insulin dosage he would inject into his body. Andrews said it pushed him to respect his body and his health.

Rhys was determined to meet Andrews in Chicago, and the Ravens told the Kinneys the best way to make it happen was to make a sign. So Rhys went to work. The sign had T1D on one side and Mark 89 Andrews on the other. To make sure Rhys, wearing his Andrews jersey, was perfectly positioned, his father got tickets by the tunnel where Ravens players entered and left the field.

The preparation paid off. After talking with Andrews before the game, Rhys made sure to wave goodbye after Baltimores 16-13 victory, and Andrews provided a souvenir by handing over his gloves. Rhys has rarely taken them off since, whether hes simulating one-handed grabs in the living room or even eating dinner.

"The amount of kindness that Mark showed my family, and the effect that he had on my son cannot be overemphasized, Brett said. "He really changed my sons life. Hell remember this forever.

The American Diabetes Association estimates 1.6 million people have Type 1 diabetes, an autoimmune disease that prevents your pancreas from producing insulin. Andrews has become one of the leading advocates for the diabetes community. Last year, he wrote a column for USA Today about how he didnt let the disease stop him from achieving his dreams. Over the years, Andrews has mentored boys and girls on eating right and staying active. Hes also counseled some who have become depressed after being diagnosed with diabetes.

"To be able to have that kind of impact, that means a lot to Mark. But, more importantly, he wants it to mean something to kids, said Martha Andrews, Marks mother. Whether you want to be a ballerina, a football player or baseball player, or you just want to be a fireman, you cant let this stop you. You've got to find a way to make it work. And Mark, he found a way. Hes lucky. But he just never took no for an answer.

Andrews life changed after a near-death experience.

Andrews experienced his first hypoglycemic incident, which caused him to lose consciousness, as a freshman at Oklahoma. His glucose levels dropped extremely low while he was napping after football practice. When Andrews roommate found him unresponsive, he shoved fruit snacks in Andrews mouth and called 911.

That kind of woke myself up and my family, Andrews said.

Andrews doctor told him about a continuous glucose monitor, which Andrews now wears every day. No more daily finger pricks. No more uncertainty about his blood sugar level.

His Dexcom G6 monitor uses a tiny sensor to send glucose levels to his phone, alerts him when his levels are too low or high and discreetly attaches to his hip. He wears it under his uniform.

Honestly, I dont even notice it, even when I get hit there, Andrews said. I forget its on me sometimes.

The glucose monitor provides real-time updates on his blood sugar level through an app, and the information is shared with family members, his agent and the Ravens' trainers. Andrews mother acknowledges she will check two or three times per day -- being a little bit nosey.

She intervenes only when she receives an alert, which indicates Andrews blood sugar level is below 60. If she sees double arrows down -- which means his levels are dropping fast -- Martha will send a one-word text to her 6-foot-5, 256-pound son: Sugar. This typically happens once a week.

Everything you need this week: Full schedule | Standings Depth charts for every team Transactions | Injuries Football Power Index rankings More NFL coverage

"Its very important to my sound mind, Martha said. "You can say, out of sight, out of mind, but you cant do that with diabetes. Its a worry 24 hours a day. But now I dont have to. I know my phone will buzz if I have to get involved.

Blood sugar levels can drop when someone exerts a lot of energy, so its important to keep an eye on Andrews when he suits up. During practices, Andrews gives his phone to a trainer, who follows him all around the field. After Andrews runs a couple of plays, hell come off the field and the trainer will give him his exact readings. In games, Andrews keeps a diabetes bag on the sideline thats filled with snacks and other supplies to help him maintain his blood sugar levels.

Ravens backup tight end Nick Boyle has become more educated about diabetes because Andrews is one of his best friends on the team. He knows what the numbers mean and often looks at them when Andrews checks the readings on his phone.

"A lot of people dont even notice it because he does such a good job of managing and going out there and doing his job, Boyle said.

During the hot and humid training camp practices, Andrews never asks for a day off and battles linebackers and defensive backs like its a playoff game. He fights for contested passes over the middle and leaps for throws in the end zone.

But the sweat and grass stains still don't cover up the chip thats been on Andrews shoulder since he slipped to the third round of the 2018 draft.

"I know just going through the combine process and all that, Im sure theres teams and people that saw me and said, 'Oh, hes a Type 1 diabetic. Thats negative, Andrews said. "I dont think that, I know that.

It didnt take the Ravens long to know they had landed a special talent. Two days into Andrews' first offseason camp, then-tight ends coach Greg Roman told everyone in a meeting Andrews has a great feel for the game and natural instincts. Andrews knew how to set up defenders and get open consistently.

By the start of the regular season, Andrews had moved past first-round pick Hayden Hurst on the depth chart. By the end of it, he had already established himself as the favorite receiver for Lamar Jackson.

Andrews has now recorded three consecutive seasons with at least 50 receptions, 700 receiving yards and five touchdowns catches. Only the Kansas City Chiefs' Travis Kelce owns a longer such streak by a tight end with five season.

We have high expectations for Mark, said Roman, who is now the Ravens' offensive coordinator. "He does for himself, and thats where it all starts.

A week before this years opener, Baltimore rewarded Andrews with a four-year, $56 million extension. At $14 million per season, Andrews is the third-highest-paid tight end in the league, trailing the San Francisco 49ers' George Kittle ($15 million per season) and Kelce ($14.3 million).

The Ravens couldnt let Jacksons most trusted target reach free agency. Whenever Jackson needs to make a play downfield, it seems like hes looking to Andrews. Andrews' acrobatic catch in the end zone was the difference in the Ravens 16-10 victory over the Cleveland Browns on Sunday night. Andrews has now caught 187 passes from Jackson, 29 more than any other Ravens player.

He makes my job way easier, Jackson said. If a defensive back is guarding him, a safety, linebacker, it doesnt really matter hes going to get open and hes going to catch a touchdown nine times out of 10.

For Andrews, hes not just playing for the Ravens. Hes playing to inspire others.

"Theres a lot of people breaking that mold and showing people that we can do anything and we can be just like anybody else. We just have to do more than the average person, Andrews said. Thats one of the things that drives me is going out there and showing people that hey, Im a Type 1 diabetic, but Im going to go out and compete with the rest of them."

The rest is here:

'He changed my son's life': How the Ravens Mark Andrews inspires others with diabetes - Baltimore Ravens Blog- ESPN - ESPN